Kathryn M. Nelson

Kathryn M. Nelson

Auto-generated profile, based on publicly available information

Kathryn M. Nelson

Department of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota 55414, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
KNKathryn M. Nelson
Kathryn M. Nelson
JDJayme L. Dahlin
Jayme L. Dahlin
JBJonathan Bisson
Jonathan Bisson
JGJames Graham
James Graham
GPGuido F. Pauli
Guido F. Pauli
MWMichael A. Walters
Michael A. Walters
Curcumin is a constituent (up to ∼5%) of the traditional medicine known as turmeric. Interest in the therapeutic use of turmeric and the relative ease of isolation of curcuminoids has led to their extensive investigation. Curcumin has recently been classified as both a PAINS (pan-assay interference compounds) and an IMPS (invalid metabolic panaceas) candidate. The likely false activity of curcumin in vitro and in vivo has resulted in >120 clinical trials of curcuminoids against several diseases. No double-blinded, placebo controlled clinical trial of curcumin has been successful. This manuscript reviews the essential medicinal chemistry of curcumin and provides evidence that curcumin is an unstable, reactive, nonbioavailable compound and, therefore, a highly improbable lead. On the basis of this in-depth evaluation, potential new directions for research on curcuminoids are discussed.

10 September 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KNKathryn M. Nelson
Kathryn M. Nelson
JBJonathan Bisson
Jonathan Bisson
GSGurpreet Singh
Gurpreet Singh
JGJames G. Graham
James G. Graham
SCShao-Nong Chen
Shao-Nong Chen
GPGuido F. Pauli
Guido F. Pauli

15 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
JDJayme L. Dahlin
Jayme L. Dahlin
KNKathryn M. Nelson
Kathryn M. Nelson
JSJessica M. Strasser
Jessica M. Strasser
DBDalia Barsyte-Lovejoy
Dalia Barsyte-Lovejoy
MSMagdalena M. Szewczyk
Magdalena M. Szewczyk
MWMichael A. Walters
Michael A. Walters
Many compounds with potentially reactive chemical motifs and poor physicochemical properties are published as selective modulators of biomolecules without sufficient validation and then propagated in the scientific literature as useful chemical probes. Several histone acetyltransferase (HAT) inhibitors with these liabilities are now routinely used to probe epigenetic pathways. We profile the most commonly used HAT inhibitors and confirm that the majority of them are nonselective interference compounds. Most (15 out of 23, 65%) of the inhibitors are flagged by ALARM NMR, an industry-developed counter-screen for promiscuous compounds. Biochemical counter-screens confirm that most of these compounds are either thiol-reactive or aggregators. Selectivity panels show many of these compounds modulate unrelated targets in vitro, while several also demonstrate nonspecific effects in cell assays. These data demonstrate the usefulness of performing counter-screens for bioassay promiscuity and assay interference, and raise caution about the utility of many widely used, but insufficiently validated, compounds employed in chemical biology.

27 July 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JSJonathan H. Shrimp
Jonathan H. Shrimp
YJYihang Jing
Yihang Jing
SGSupuni Thalalla Gamage
Supuni Thalalla Gamage
KNKathryn M. Nelson
Kathryn M. Nelson
JHJoseph Han
Joseph Han
JMJordan L. Meier
Jordan L. Meier

11 May 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
KNKathryn M. Nelson
Kathryn M. Nelson
JDJayme L. Dahlin
Jayme L. Dahlin
JBJonathan Bisson
Jonathan Bisson
JGJames Graham
James Graham
GPGuido F. Pauli
Guido F. Pauli
MWMichael A. Walters
Michael A. Walters

9 April 2018 in Current Protocols in Chemical Biology
Verified
Journal Article
Open access
PDF file
JDJayme L. Dahlin
Jayme L. Dahlin
MCMatthew Cuellar
Matthew Cuellar
GSGurpreet Singh
Gurpreet Singh
KNKathryn M. Nelson
Kathryn M. Nelson
JSJessica M. Strasser
Jessica M. Strasser
MWMichael A. Walters
Michael A. Walters
Nonspecific target engagement by test compounds and purported chemical probes is a significant source of assay interference and promiscuous bioactivity in high-throughput screening (HTS) and chemical biology. Most counter-screens for thiol-reactive compounds utilize mass spectrometry or fluorescence detection, as well as nonproteinaceous reporters like glutathione that may not always approximate the reactivity of protein side chains. By contrast, a La assay to detect reactive molecules by nuclear magnetic resonance (ALARM NMR) is an industry-developed protein-based [1H-13C]-heteronuclear multiple quantum coherence NMR counter-screen to identify nonspecific protein interactions by test compounds by reporting their tendencies to modulate the human La antigen conformation. This article is a user's guide to the production of the 13C-labeled La antigen reporter protein and reaction of test compounds with this reporter protein, as well as the collection and analysis of characteristic NMR spectra. Combined with other assay interference counter-screens, this assay will enhance chemical biology by helping researchers better prioritize chemical matter, which will increase the number of tractable HTS screening actives and aid in the development of better chemical probes. © 2018 by John Wiley & Sons, Inc.